THOUSAND OAKS, Calif., Sept. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to invest more than $600 million in a new, state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California.
The center is designed to bring together researchers, engineers and scientists across disciplines to enhance collaboration and accelerate the discovery of next-generation therapeutics for patients with the most serious diseases. The building will feature advanced automation and digital capabilities, empowering scientists with the tools and environment needed to drive scientific excellence and advancements in biotechnology.
Amgen's long-standing commitment to U.S. innovation and state-of-the-art operations is reflected in more than $40 billion invested in manufacturing and research and development since the passage of the Tax Cuts and Jobs Act (TCJA) of 2017. This investment includes over $5 billion in direct capital expenditures in the U.S. The enactment of pro-growth tax policies in TCJA, extended and reinforced by the One Big Beautiful Bill Act of 2025, further facilitates Amgen's ability to invest domestically in cutting-edge science and manufacturing.
"At Amgen, we're continuing to invest in the future of American science and innovation," said Robert A. Bradway, chairman and chief executive officer at Amgen. "This new center will empower our scientists with the tools and collaborative environment they need to shape the next era of scientific discovery and advance medicines that improve human health."
The new center for science and innovation enhances the company's global network of sites, leveraging decades of operational expertise and technological advancements.
Construction is expected to begin in Q3 2025 and create hundreds of U.S. jobs. Amgen has been headquartered in Thousand Oaks, California, part of the greater Los Angeles region, since the company's founding more than 45 years ago.
The announcement builds on other recent investments from the company including a $900 million expansion of its manufacturing facility in Central Ohio and a $1 billion investment to build a second manufacturing plant in Holly Springs, North Carolina.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.